Clinical Trials Logo

Any Solid Tumor clinical trials

View clinical trials related to Any Solid Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT04521686 Active, not recruiting - Glioma Clinical Trials

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Start date: October 16, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.

NCT ID: NCT03157128 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

LIBRETTO-001
Start date: May 2, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.